secwatch / observer
8-K filed May 16, 2024, 7:59 PM ET ticker BJDX CIK 0001704287
other material confidence high sentiment neutral materiality 0.75

Bluejay Diagnostics increases authorized shares from 7.5M to 50M; shareholders approve reverse stock split up to 1:10

Bluejay Diagnostics, Inc.

item 5.03item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001213900-24-044034
form_type
8-K
ticker
BJDX
cik
0001704287
company_name
Bluejay Diagnostics, Inc.
filed_at
2024-05-16T23:59:59+00:00
discovered_at
2026-05-14T18:03:19.666570+00:00
generated_at
2026-06-01T21:27:34.131286+00:00
sec_items
["5.03", "5.07", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001213900-24-044034
json_url
https://secwatch.observer/filing/0001213900-24-044034.json
markdown_url
https://secwatch.observer/filing/0001213900-24-044034.md
text_url
https://secwatch.observer/filing/0001213900-24-044034.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/0001213900-24-044034-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1704287/000121390024044034/ea020636401-8k_bluejay.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

07b28d4d3cce60f812370222feb01670e74f8b33

Bluejay Diagnostics, Inc.: Increased authorized common shares from 7,500,000 to 50,000,000 via amendment to certificate of incorporation (effective 2024-05-14).

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

2a04baf953ddd8812f00cb43b1360bbf9dcce743

Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm at the 2024-05-14 meeting.

Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

b90d72d3d85c39721516b04f2248c25156ca650f

Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2024-05-14 meeting.

Proposal 2. Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock.

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

c18b006103b1f92dbc41431f3c0124c43315061c

Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-14 meeting.

Proposal 3. Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to effect a reverse stock split of all of the Company’s outstanding shares of common stock by one of several fixed ratios between 1-for-2 and 1-for-10 (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined in the future by the Company’s board of directors, in its sole discretion and without further action by the Company’s stockholders.

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

c5dfd89f6b5f13d00f02616168e0ef685a765547

Bluejay Diagnostics, Inc. shareholders approved Election of directors at the 2024-05-14 meeting.

Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani and Douglas Wurth to serve as directors until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

Comparable filings

CVNA

Carvana stockholders approve 5-for-1 stock split, adopt new 2026 incentive plan

CARVANA CO. May 6, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

At the Annual Meeting, the Company's stockholders approved an amendment (the "Amendment") to the Company's Amended and Restated Certificate of Incorporation to effect a five-for-one forward stock split of the Company's Class A common stock and Class B common stock (the "Stock Split") and to proportionately increase the number of authorized shares of Class A common stock and Class B common stock (the "Authorized Share Increase").

Filing page SEC filing

SLXN

Silexion shareholders approve 50M share increase, expanded equity plan, and 1-for-10 reverse split

Silexion Therapeutics Corp May 5, 2026, 7:59 PM ET other_material Items 5.03, 5.07, 9.01

same fact type: governance_change same SEC item: 5.03, 5.07, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

At the extraordinary general meeting of Silexion Therapeutics Corp (the “ Company ”) originally held on April 28, 2026 and reconvened on May 5, 2026 (the “ Meeting ”), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company’s amended and restated memorandum of association (the “ Memorandum Amendment”) , which increased the Company’s authorized share capital, as described in Item 5.07 below.

Filing page SEC filing

BRCC

BRCC regains NYSE minimum share price compliance; reverse split approved but not needed

BRC Inc. June 2, 2026, 6:18 AM ET other_material Items 5.07, 7.01, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

Comparable filing

Proposal 2. Ratification of the Appointment of the Independent Registered Public Accountants The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: For Against Abstain Broker Non-Votes 144,256,280 1,491,239 195,288 0

Filing page SEC filing

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

MDAI

Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026

Spectral AI, Inc. June 1, 2026, 4:01 PM ET other_material Items 5.07, 7.01, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.

Comparable filing

The stockholders voted at the Annual Meeting to approve the Hudson Bay Proposal. Votes For Votes Against Abstentions Broker Non-Votes 9,272,055 1,838,069 134,311 6,023,135

Filing page SEC filing

SAGU

Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE

Shreya Acquisition Group May 11, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.

Filing page SEC filing

PSEC

Prospect Capital enters $400M at-the-market preferred stock offering; reclassifies 16M common shares

PROSPECT CAPITAL CORP May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.03, 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

On May 8, 2026, in connection with the Offering, the Company filed Articles Supplementary (the “Articles Supplementary”) with the State Department of Assessments and Taxation of Maryland (“SDAT”), reclassifying and designating 16,000,000 authorized and unissued shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), into shares of Series A Preferred Stock.

Filing page SEC filing

HAWK

HawkEye 360 closes IPO on May 8; files amended charter and bylaws

HawkEye 360, Inc. May 8, 2026, 7:59 PM ET other_material Items 5.03, 9.01

same fact type: governance_change same SEC item: 5.03, 9.01 same event type: other_material similar materiality

This filing

On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.

Comparable filing

Effective as of May 8, 2026, the Company adopted Amended and Restated Bylaws (the “Restated Bylaws”) in connection with the closing of the IPO.

Filing page SEC filing

Source: SEC EDGAR
accession 0001213900-24-044034
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.